LigaChem Biosciences Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Yong Kim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 3.6% |
| Management average tenure | no data |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%
Nov 29
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07
CEO
Yong Kim (68 yo)
no data
Tenure
Mr. Yong Zu Kim serves as the Chief Executive Officer, President and Director at LigaChem Biosciences Inc. (formerly known as LegoChem Biosciences, Inc.). Mr. Kim has of experience in drug discovery and de...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | no data | 3.57% ₩ 125.4b | |
| CFO, COO | no data | no data | 0.50% ₩ 17.5b | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | 0.0041% ₩ 143.8m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Outside Director | less than a year | no data | no data |
0.8yrs
Average Tenure
63yo
Average Age
Experienced Board: A141080's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LigaChem Biosciences Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mujinn Lee | Cape Investment & Securities Co., Ltd. |
| Seohyun Lee | Citigroup Inc |
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |